{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Heparin&page=2",
    "query": {
      "condition": "Heparin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Heparin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T08:10:04.819Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02744092",
      "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Venous Thromboembolism",
        "Deep Vein Thrombosis (DVT)",
        "Pulmonary Embolism (PE)",
        "Blood Clot"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Fondaparinux",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 811,
      "start_date": "2016-12-13",
      "completion_date": "2021-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 151,
      "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02744092"
    },
    {
      "nct_id": "NCT07250763",
      "title": "Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Deep Vein Thrombosis",
        "Atrial Fibrillation",
        "Acute Cardiac Syndrome",
        "Mechanical Heart Valve Recipients"
      ],
      "interventions": [
        {
          "name": "Initial Heparin Dose Modification",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2023-09-20",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Alexandria, Virginia",
      "locations": [
        {
          "city": "Alexandria",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07250763"
    },
    {
      "nct_id": "NCT02707263",
      "title": "Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "intravenous continuous infusion of heparin (IV UFH)",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-03",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02707263"
    },
    {
      "nct_id": "NCT02526485",
      "title": "Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heparin-induced Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-03",
      "completion_date": "2018-09-05",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526485"
    },
    {
      "nct_id": "NCT01312935",
      "title": "Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Percutaneous Coronary Intervention",
        "Coronary Artery Disease (CAD)",
        "Angioplasty"
      ],
      "interventions": [
        {
          "name": "PMX-60056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PolyMedix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2011-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-05-17",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 3,
      "location_summary": "South Bend, Indiana • Detroit, Michigan • Rapid City, South Dakota",
      "locations": [
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01312935"
    },
    {
      "nct_id": "NCT04764396",
      "title": "Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreas",
        "Mass Lesion"
      ],
      "interventions": [
        {
          "name": "Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-03-12",
      "completion_date": "2021-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04764396"
    },
    {
      "nct_id": "NCT00001311",
      "title": "Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "heparin-surface modified intraocular lens",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "1992-04",
      "completion_date": "2001-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001311"
    },
    {
      "nct_id": "NCT01392508",
      "title": "IMproved PREdiction of Severe Sepsis in the Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Inflammatory Response Syndrome (SIRS)",
        "Sepsis",
        "Severe Sepsis",
        "Septic Shock"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Axis Shield Diagnostics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2011-03",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2017-04-14",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Camden, New Jersey",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01392508"
    },
    {
      "nct_id": "NCT00317395",
      "title": "Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Otamixaban (XRP0673)",
          "type": "DRUG"
        },
        {
          "name": "unfractionated heparin",
          "type": "DRUG"
        },
        {
          "name": "eptifibatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3241,
      "start_date": "2006-06",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2014-12-03",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317395"
    },
    {
      "nct_id": "NCT03113721",
      "title": "Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sepsis",
        "Septic Shock",
        "Sepsis With Acute Organ Dysfunction"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Axis Shield Diagnostics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 571,
      "start_date": "2017-03-27",
      "completion_date": "2019-03-01",
      "has_results": false,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-06-11T08:10:04.819Z",
      "location_count": 5,
      "location_summary": "Philadelphia, Pennsylvania • York, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "York",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113721"
    }
  ]
}